Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company focused on the development, manufacturing, and commercialisation of differentiated formulations. As of June 30, 2025, the company holds approvals for 72 products under the US FDA’s ANDA and NDA framework, with 66 products currently commercialised. Its presence in the US generic pharmaceutical market, valued at USD 2,455.7 million, generated revenue of USD 195 million for Rubicon in Fiscal 2024. The company has an additional 17 products awaiting US FDA approval and 63 products in various stages of development, reflecting a consistent pipeline for future growth.
Rubicon Research also markets over 350 SKUs to 96 customers, including major wholesalers covering more than 90% of wholesale drug distribution in the US. The company extends its operations internationally with 48 product applications across Australia, the UK, Singapore, Saudi Arabia, and the UAE. Its services include contract manufacturing for select customers in India, Australia, and New Zealand. Rubicon operates three manufacturing facilities in India and maintains two US FDA inspected R&D centres in India and Canada, supporting both domestic and international product development.